ArticleFrontiers in microbiology2021
A High Rate of Recurrent Vulvovaginal Candidiasis and Therapeutic Failure of Azole Derivatives Among Iranian Women.
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Epidemiology of vulvovaginal candidiasis in China: a six-year retrospective single-center study from a tertiary obstetrics and gynecology hospital in Shanghai.Microbiology spectrum · 2026Article
- Advances in vulvovaginal candidiasis research: a comprehensive review from epidemiology, diagnosis, treatment to resistance mechanisms.Frontiers in microbiology · 2026Review
- Recurrent Vulvovaginal Candidosis and Its Underlying Mechanisms: A Systematic Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Knowledge of Vulvovaginal Candidiasis Characteristics, Signs, Symptoms, and Appropriate Treatment Among Portuguese Pharmacy Professionals.Healthcare (Basel, Switzerland) · 2025Article
- Prevalence, drug resistance and genetic diversity ofMycology · 2025Article
- New insights toward personalized therapies for vulvovaginal candidiasis and vaginal co-infections.Frontiers in microbiology · 2025Review
- Integrating Clinical and Microbiological Expertise to Improve Vaginal Candidiasis Management.Mycopathologia · 2024Article
- Chiral Fluorescent Antifungal Azole Probes Detect Resistance, Uptake Dynamics, and Subcellular Distribution inJACS Au · 2024Article
- The Increasing Trend of Triazole-Resistant Candida from Vulvovaginal Candidiasis.Infection and drug resistance · 2024Article
- Inflammatory cytokine signalling in vulvovaginal candidiasis: a hot mess driving immunopathology.Oxford open immunology · 2024Review
- Article
- Phenotypic characterization and antifungal susceptibility profile of Candida isolates from women with vulvovaginal candidiasis at a community health center linked to a teaching institution in the Sub-Himalayan region of North India.Journal of family medicine and primary care · 2023Article
- Evaluation of the Therapeutic Effect of 15 ppm Silver Nanoparticle Spray Compared to Clotrimazole 1% on Candida Vaginitis: A Randomized Controlled Clinical Trial.Journal of family & reproductive health · 2023Article
- Combination of Farnesol with Common Antifungal Drugs: Inhibitory Effect againstMedicina (Kaunas, Lithuania) · 2023Article
- Biofilm Formation and Aspartyl Proteinase Activity and Their Association with Azole Resistance AmongInfection and drug resistance · 2023Article
- A New Approach for the Treatment of Recurrent Vulvovaginal Candidiasis with a Combination of Pea Protein, Grape Seed Extract, and Lactic Acid Assessed In Vivo.Journal of fungi (Basel, Switzerland) · 2022Article
- Importance of Candida infection and fluconazole resistance in women with vaginal discharge syndrome in Namibia.Antimicrobial resistance and infection control · 2022Article
- Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis.Frontiers in immunology · 2022Article
- The Antibiofilm Role of Biotics Family in Vaginal Fungal Infections.Frontiers in microbiology · 2022Review
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.Drugs · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent vulvovaginal candidiasis (RVVC) is one of the most prevalent fungal infections in humans, especially in developing countries; however, it is underestimated and regarded as an easy-to-treat condition. RVVC may be caused by dysbiosis of the microbiome and other host-, pathogen-, and antifungal drug-related factors. Although multiple studies on host-related factors affecting the outcome have been conducted, such studies on
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.